-
Dr. Peter Schmid：KEYNOTE-522 Study OS Results Update, Pembrolizumab Reshapes the Treatment Landscape for Early TNBC patients
At the 2024 ESMO Congress, Dr. Peter Schmid from Barts Cancer Institute, Queen Mary University of London shared the overall survival data from the KEYNOTE-522 study with a follow-up of 75.1 months. The long-term follow-up results of the study showed that the combination of immunotherapy and chemotherapy significantly extended the event-free survival and overall survival…
-
Sino-Foreign Dialogue on the Banks of the Yangtze River: Experts’ High-end Talks to Explore the Frontiers and Cooperation Paths of Viral Hepatitis Res
Hepatology Digest：Both of you have made remarkable achievements in the research field of hepatitis virus infections. May I ask what are the breakthrough discoveries regarding new therapeutic targets for hepatitis…
-
Dr Wai-Kay Seto’s Team: Optimized Glycemic Control Reduces Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Diabetes
Introduction Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the third leading cause of cancer-related deaths globally. What makes HCC particularly dangerous is its high…
-
China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen
Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme “Patient-Centric, Shared Future.” Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology…
-
Chinese Society of Clinical Oncology (CSCO) Elects New Council Members
Election of New Council Members Professor Xu Ruihua, the President of CSCO and from Sun Yat-sen University Cancer Center, delivered a comprehensive and in-depth report on the work of the…
-
Dr. Peiqi Zhao: New Drug Developments and Optimized Management – Upgrading the Comprehensive Treatment Strategy for Follicular Lymphoma
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of…
-
Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal
In April 2024, the 115th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA. As a global bellwether for new cancer drug development, the AACR meeting showcased numerous cutting-edge research findings in the field of oncology. One such study, conducted by Dr. Lin Shen’s team from Peking Cancer…
-
Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy
The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and…
Connecting Medical Expertise through Media